Scheme Completed
Alkermes acquisition of Avadel Pharmaceuticals
NASDAQ: AVDL
Advisers
- Target
- Avadel Pharmaceuticals
- Acquirer
- Alkermes
- Target based in
- Ireland
- Buyer based in
- Ireland
- Structure
- Scheme of arrangement
- Completed
- 12 Feb 2026
- Sector
- Pharma
- Tags
- Pharma, Biotech
In the league tables
Similar deals
- Fresenius acquisition of mAbxience Oct 2026 · US$1.9bn · Biotech
- Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug Jul 2026 · US$250m · Pharma
- Hansoh Pharmaceutical Group Co. stake in Avere Therapeutics Jul 2026 · Biotech
- Vertex Pharmaceuticals acquisition of Crinetics Pharmaceuticals Jul 2026 · US$10bn · Biotech
- Zymeworks acquisition of Theravance Biopharma Jun 2026 · US$929m · Pharma
Sources
- 12 Feb 2026 Press release (EX-99.1, exhibit), For Investors: Sandy Coombs +1 sec.gov
- 12 Feb 2026 Press release (EX-99.1, exhibit), For Media: Katie Joyce +1 781 249 8927 sec.gov


